In a filing, Resmed Inc revealed its Officer Farrell Michael J. acquired Company’s shares for reported $2.06 million on Jul 07 ’25. In the deal valued at $256.72 per share,8,009 shares were bought.
Then, FARRELL PETER C sold 945 shares, generating $241,438 in total proceeds. Upon selling the shares at $255.49, the Director now owns 68,273 shares.
Before that, Sandercock Brett sold 3,883 shares. Resmed Inc shares valued at $997,892 were divested by the Chief Financial Officer at a price of $256.99 per share. As a result of the transaction, Sandercock Brett now holds 84,283 shares, worth roughly $21.61 million.
Morgan Stanley initiated its Resmed Inc [RMD] rating to an Overweight in a research note published on March 19, 2025; the price target was $280. A number of analysts have revised their coverage, including Morgan Stanley’s analysts, who began to cover the stock in mid March with a ‘”an Overweight”‘ rating. Goldman began covering RMD with “Buy” recommendation on January 16, 2025. Piper Sandler started covering the stock on January 10, 2025. It rated RMD as “a Neutral”.
Price Performance Review of RMD
On Monday, Resmed Inc [NYSE:RMD] saw its stock fall -0.21% to $256.41. Over the last five days, the stock has gained 0.49%. Resmed Inc shares have risen nearly 35.42% since the year began. Nevertheless, the stocks have risen 12.12% over the past one year. While a 52-week high of $263.05 was reached on 01/30/25, a 52-week low of $188.56 was recorded on 04/07/25.
Levels Of Support And Resistance For RMD Stock
The 24-hour chart illustrates a support level at 255.07, which if violated will result in even more drops to 253.72. On the upside, there is a resistance level at 258.07. A further resistance level may holdings at 259.72.
How much short interest is there in Resmed Inc?
A steep rise in short interest was recorded in Resmed Inc stocks on 2025-06-13, dropping by -1.01 million shares to a total of 9.93 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-15 was 10.93 million shares. There was a decline of -10.12%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on December 13, 2024 when Stifel began covering the stock and recommended ‘”a Hold”‘ rating along with a $250 price target.
